Lung Cancer: 854 Real Stories

854 stories match lung cancer. 428 of them mention chemotherapy.

Cancer Stories

A patient, who was diagnosed with Stage IV Lung AdenocarcinomaLung Cancer

A regressed choroidal metastasis during EGFR-targeted lung cancer treatment

Patient Info: Anonymized, Female, 40s | Stage IV

Biomarkers: EGFR exon 19 deletion.

Metastatic Site: liver; bone; central nervous system; right choroid

The right choroidal metastasis appeared inactive and regressed during systemic treatment, visual acuity remained 20/20, and no local eye treatment was required.

PubMed Central
OutcomeResponding Well
Kathy, who was diagnosed with Small Cell Lung CancerLung Cancer

Small Cell Lung Cancer: Kathy's Patient Story

Patient Info: Kathy Meyer, Female, 50s

Kathy lived for 13 years after a small cell lung cancer diagnosis and passed away on April 25, 2020 at age 63 after COVID-19 rapidly worsened her health in the setting of lung cancer and COPD.

Lung Cancer Research Foundation
OutcomeIn Memory
A patient, who was diagnosed with Lung AdenocarcinomaLung Cancer

NRG1-Fusion Lung Cancer With a 24-Month Response to Afatinib

Patient Info: Anonymized, Female, 50s | Stage Metastatic/Advanced

Biomarkers: NRG1 fusion; KRAS/EGFR/ALK/ROS1/ERBB2 alterations not detected

Metastatic Site: left lung

Her cancer progressed during atezolizumab, and she died in May 2019.

PubMed Central
OutcomeIn Memory
A patient, who was diagnosed with Lung AdenocarcinomaLung Cancer

Metastatic NRG1-Fusion Lung Cancer Responding to Long-Term Afatinib

Patient Info: Anonymized, Female, 60s | Stage Metastatic/Advanced

Biomarkers: CD74-NRG1 fusion

Metastatic Site: lungs

As of February 2020, she remained on afatinib 30 mg daily with an ongoing partial response after 27 months.

PubMed Central
OutcomeResponding Well
A patient, who was diagnosed with Stage IV Lung AdenocarcinomaLung Cancer

Stage IV Mucinous Lung Cancer Treated With Afatinib and Surgery

Patient Info: Anonymized, Female, 40s | Stage IV

Biomarkers: CD74-NRG1 fusion; ALK/ROS1/EGFR/BRAF/KRAS/MET/HER2 wild type; PD-L1 initially not expressed and later 0%-20%

Metastatic Site: bilateral lungs|bone|right adrenal gland

She was alive and receiving treatment after bone and right-adrenal progression at the latest follow-up.

PubMed Central
OutcomeCare Ongoing
A patient, who was diagnosed with Lung AdenocarcinomaLung Cancer

Recurrent Mucinous Lung Cancer With Dose-Dependent Afatinib Responses

Patient Info: Anonymized, Female, Under 40 | Stage Metastatic/Advanced

Biomarkers: SDC4-NRG1 fusion; PD-L1 not expressed; low tumor mutation burden

Metastatic Site: bilateral lungs

She had progressive lung disease after several targeted-treatment attempts and was receiving paclitaxel with bevacizumab as of February 2020.

PubMed Central
OutcomeCare Ongoing
Deborah, who was diagnosed with Stage I Lung CancerLung Cancer

Stage I Lung Cancer: Deborah's Patient Story

Patient Info: Deborah Schroeder, Female | Stage I

As of December 2020, Deborah had completed 3 separate 4-day SBRT courses for Stage I lung cancers and remained under monitoring for about 10 tiny lung nodules that had been stable for years.

MD Anderson
OutcomeCare Ongoing
Oswald, who was diagnosed with Stage IV Lung CancerLung Cancer

Stage IV Lung Cancer: Oswald's Patient Story

Patient Info: Oswald Peterson, Male | Stage IV

Metastatic Site: Lymph nodes; Spine

As of December 2020, Oswald described dramatic recovery after immunotherapy for Stage IV lung cancer, returning to the gym, travel, and normal activities; the source did not explicitly report NED or a maintenance schedule.

YouTube (ZH search)
OutcomeResponding Well
Saila, who was diagnosed with Stage IV Non-Small Cell Lung CancerLung Cancer

Stage IV EGFR Non-Small Cell Lung Cancer: Saila's Patient Story

Patient Info: Saila Hanninen, Under 40 | Stage IV

Biomarkers: EGFR mutation

After progression on earlier EGFR-directed treatment and other therapies, Saila began chemotherapy and her cancer was stable at the time of the story.

Dana-Farber
OutcomeStable Disease
A patient, who was diagnosed with Stage IV Lung AdenocarcinomaLung Cancer

Lung adenocarcinoma first presented through skin and haemorrhagic brain metastases

Patient Info: Anonymized, Female, 60s | Stage IV

Biomarkers: TTF-1-positive; CK7-positive; CEA-positive; PD-L1 10%; EGFR-negative; ALK-negative; ROS1-negative; BRAF-negative

Metastatic Site: skin|brain

Her condition declined rapidly after brain radiation, systemic therapy could not be started, and she died from metastatic lung cancer within 6 weeks of presentation.

PubMed Central
OutcomeIn Memory
A patient, who was diagnosed with Stage IV Non-Small Cell Lung CancerLung Cancer

Advanced Lung Cancer With Extreme White Blood Cell Counts and Poor Circulation

Patient Info: Anonymized, Female, 60s | Stage IV

Biomarkers: PD-L1 70%

Metastatic Site: contralateral lung|bone (left iliac)

After a mixed but mildly improved response to three pembrolizumab cycles, she developed severe paraneoplastic leukocytosis, arterial ischaemia, and acute respiratory failure and died after choosing comfort measures.

PubMed Central
OutcomeIn Memory
A patient, who was diagnosed with Small Cell Lung CancerLung Cancer

Right Small Cell Lung Cancer Progressing During Pembrolizumab

Patient Info: Anonymized, Male, 70+ | Stage Metastatic/Advanced

Metastatic Site: pleura|liver

The right small cell lung cancer progressed with malignant pleural effusion and liver metastases. His condition declined rapidly, and he died on March 8, 2018.

PubMed Central
OutcomeIn Memory
A patient, who was diagnosed with Lung AdenocarcinomaLung Cancer

Left Lung Adenocarcinoma With Complete Response to Pembrolizumab

Patient Info: Anonymized, Male, 70+

Biomarkers: PD-L1 tumor proportion score 100%; no driver gene mutation detected

The left adenocarcinoma had a complete response to pembrolizumab. He nevertheless died on March 8, 2018, as the separate right-sided small cell lung cancer progressed.

PubMed Central
OutcomeIn Memory
A patient, who was diagnosed with Stage IV Non-Small Cell Lung CancerLung Cancer

Metastatic Lung Cancer Responded Completely After a Change in Immunotherapy

Patient Info: Anonymized, Male, 70+ | Stage IV

Biomarkers: TTF-1-positive; napsin-positive; PD-L1 0%; high tumour mutational burden; no actionable mutations

Metastatic Site: bone (left iliac bone, acetabulum and thoracic…

After progression on nivolumab, atezolizumab produced a complete response by the 6-month scan; after 35 cycles, the response remained sustained, he was alive and well, and no immune-related adverse effects were documented.

PubMed Central
OutcomeResponding Well
A patient, who was diagnosed with Small Cell Lung CancerLung Cancer

Small-Cell Lung Cancer First Appeared as Rapidly Worsening Nerve Damage

Patient Info: Anonymized, Female, 60s

Biomarkers: Anti-Hu-positive; anti-CV2/CRMP5-positive; anti-SOX1-positive

Despite six cycles of carboplatin and etoposide and intensive treatment for the paraneoplastic neuropathy, her neurological condition progressed; after a thrombocytopenia-related brain haemorrhage, she entered palliative care and died within weeks.

PubMed Central
OutcomeIn Memory
A patient, who was diagnosed with Stage IV Lung AdenocarcinomaLung Cancer

Lung cancer response to pembrolizumab complicated by severe kidney injury

Patient Info: Anonymized, Male, 70+ | Stage IV

The lung tumor had decreased after 5 pembrolizumab courses and had not progressed again by hospital discharge. The kidney complication required temporary dialysis but resolved, with creatinine 0.91 mg/dL at 8-month follow-up.

PubMed Central
OutcomeResponding Well
A patient, who was diagnosed with Small Cell Lung CancerLung Cancer

Small Cell Lung Cancer With Unusual Colon Metastases After Afatinib

Patient Info: Anonymized, Female, 60s | Stage Metastatic/Advanced

Biomarkers: EGFR exon 19 deletion

Metastatic Site: liver|adrenal glands|bone|brain|ascending…

The cancer progressed after an initial response to afatinib, with new brain and colon metastases. She died from respiratory failure on August 1, 2016.

PubMed Central
OutcomeIn Memory
A patient, who was diagnosed with Stage IV Lung AdenocarcinomaLung Cancer

Long response to afatinib in EGFR-mutated lung cancer

Patient Info: Anonymized, Male, 60s | Stage IV

Biomarkers: EGFR L861Q mutation; EGFR G719X mutation

Metastatic Site: multiple bilateral ribs

CT at 30 months showed no recurrence, and he remained well 32 months after starting afatinib.

PubMed Central
OutcomeResponding Well
A patient, who was diagnosed with Stage IV Lung CancerLung Cancer

Pleomorphic lung cancer responding to pembrolizumab plus chemotherapy

Patient Info: Anonymized, Male, 60s | Stage IV

Biomarkers: PD-L1 tumor proportion score >75%; EGFR negative; ROS1 negative; ALK fusion negative

Metastatic Site: right 8th rib, left adrenal gland

His general condition improved as the tumors shrank, and he remained well 7 months after diagnosis with maintenance pembrolizumab planned.

PubMed Central
OutcomeResponding Well
A patient, who was diagnosed with Lung AdenocarcinomaLung Cancer

ROS1-positive lung adenocarcinoma presenting with cancer spread across the abdomen

Patient Info: Anonymized, Male, 50s | Stage Metastatic/Advanced

Biomarkers: ROS1 rearrangement-positive; high PD-L1 expression.

Metastatic Site: peritoneum and omentum; pleura

Crizotinib relieved his respiratory and abdominal symptoms, and six-month imaging showed no residual disease or progression while treatment continued.

PubMed Central
OutcomeResponding Well